Progressive disease assessed by RECIST v1.1 reduced overall survival to 13.9 months compared to 29.3 months without progression (p=0.014) in sarcoma patients with pulmonary metastases.
Observational (n=92)
No
Does RECIST v1.1 progressive disease predict overall survival in sarcoma patients with pulmonary metastasis?
The appearance of new pulmonary metastases, rather than a 20% increase in lesion size, is the primary driver of poor overall survival in metastatic sarcoma, suggesting RECIST v1.1 needs sarcoma-specific adaptations.
Effect estimate: p=0.014
Absolute Event Rate: 13.9% vs 29.3%
p-value: p=0.014
Abstract Purpose Response assessment in the treatment of metastatic sarcoma primarily depends on imaging, as no established clinical or serological biomarkers reliably predict survival outcomes. This study evaluates the utility of Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in predicting overall survival (OS) in sarcoma patients with pulmonary metastases. Methods We selected consecutive study subjects from a prospective registry based on the following criteria: (1) available CT imaging at first diagnosis of pulmonary metastases from sarcoma, (2) available follow-up CT imaging within 16 weeks of systemic therapy initiation, (3) documentation of OS. Volumetric segmentation of up to 5 lung metastases was performed over time. Progressive disease (PD) was defined as increase of the unidimensional sum of lesions ≥ 20% or appearance of new metastases according to RECIST v1.1. Kaplan-Meier survival analyses were performed. P values < 0.05 were considered statistically significant. Results Ninety-two patients were included (median age: 58 years; 50% female). Average time of follow-up CT was 67 days after baseline imaging. Patients with PD on first follow-up imaging ( n = 24; 26%) showed significantly shorter OS (13.9 months vs. 29.3 months; p = 0.014). The unidimensional growth threshold of 20% proposed by RECIST did not stratify OS (14.6 months vs. 26.8 months, p = 0.221). The appearance of new metastases ( n = 16; 17%) indicated significantly shorter OS (7.8 months vs. 27.0 months; p < 0.001) and was frequently observed even in patients with decreasing size of existing metastases ( n = 7; 8%). Conclusion Imaging progression patterns of pulmonary metastatic sarcoma demonstrate distinct associations with OS, highlighting the need for sarcoma-specific adaptations to established response criteria.
Gold et al. (Thu,) conducted a observational in Patients with sarcoma and pulmonary metastases undergoing systemic therapy (n=92). Systemic therapy with response assessed by RECIST v1.1 criteria vs. No progressive disease or no new metastases on follow-up imaging was evaluated on Overall survival (OS) stratified by RECIST v1.1 progression status (p=0.014, p=0.014). Progressive disease assessed by RECIST v1.1 reduced overall survival to 13.9 months compared to 29.3 months without progression (p=0.014) in sarcoma patients with pulmonary metastases.